New developments in celiac disease treatments
August 12, 2024Franziska Buriánek, Christian Gege, Petar MarinkovićDrug Discovery TodayPublished: August 2024https://doi.org/10.1016/j.drudis.2024.104113Synthesis and Characterization of DHODH Inhibitors Based on the Vidofludimus Scaffold with Pronounced Anti-SARS-CoV-2 Activity
August 8, 2024Christian Gege, Friedrich Hahn, Christina Wangen, Sigrun Häge, Alexandra Herrmann, Nadja Uhlig, Valentina Eberlein, Leila Issmail, Robert Klopfleisch, Thomas Grunwald, Manfred Marschall,…Validation of nuclear receptor RORγ isoform 1 as a novel host-directed antiviral target based on the modulation of cholesterol levels
December 18, 2023Christina Wangen, Andrea Raithel, Julia Tillmanns, Christian Gege, Alexandra Herrmann, Daniel Vitt, Hella Kohlhof, Manfred Marschall, and Friedrich HahnAntiviral ResearchPublished:…Development of a Potent Nurr1 Agonist Tool for In Vivo Applications
April 26, 2023Jan Vietor, Christian Gege, Tanja Stiller, Romy Busch, Espen Schallmayer, Hella Kohlhof, Georg Höfner, Jörg Pabel, Julian A. Marschner, and…Safety, Tolerability, and Pharmacokinetics of IMU-935, a Novel Inverse Agonist of Retinoic Acid Receptor–Related Orphan Nuclear Receptor γt: Results From a Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study
March 31, 2023Thomas M. Polasek, Indika Leelasena, Irina Betscheider, Marija Marolt, Hella Kohlhof, Daniel Vitt, Frank Fliegert, Andreas R. MuehlerClinical Pharmacology in…Mechanistic Impact of Different Ligand Scaffolds on FXR Modulation Suggests Avenues to Selective Modulators
November 2, 2022Jan Heering, Nathalie Jores, Whitney Kilu, Espen Schallmayer, Evelyn Peelen, Andreas Muehler, Hella Kohlhof, Daniel Vitt, Verena Linhard, Santosh L.…Safety and Efficacy of Vidofludimus Calcium in Patients Hospitalized with COVID-19: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial
October 17, 2022Maria J. G. T. Vehreschild, Petar Atanasov, Kateryna Yurko, Cristian Oancea, Georgi Popov, Valentina Smesnoi, Gheorghe Placinta, Hella Kohlhof, Daniel…A double-blind, randomized, placebo-controlled phase 2 trial evaluating the selective dihydroorotate dehydrogenase inhibitor vidofludimus calcium in relapsing-remitting multiple sclerosis
June 15, 2022Robert J. Fox, Heinz Wiendl, Christian Wolf, Nicola De Stefano, Johann Sellner, Viktoriia Gryb, Konrad Rejdak, Plamen Stoyanov Bozhinov, Nataliya…Inhibitors of dihydroorotate dehydrogenase cooperate with molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication
May 10, 2022Kim M. Stegmann et al.iSciencePublished: May 20, 2022https://doi.org/10.1016/j.isci.2022.104293A Pilot Study of Vidofludimus Calcium for Treatment of Primary Sclerosing Cholangitis
March 15, 2022Elizabeth J. Carey, John Eaton, Mitchell Clayton, Andrea Gossard, Sara Iqbal, Hamid Ullah, Nan Zhang, Richard Butterfield, Keith D. LindorHepatology…
